TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7976143

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 micrograms.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms.kg‐1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (Propofol alone)
Number of subjects: 120
Study: 2522899

Group type: EXPERIMENTAL
Intervention: Induction of ovulation with pFSH/hCG
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Induction of ovulation with pFSH/hMG/hCG
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Down-regulation of the ovaries with a GnRH analogue (Decapeptyl)
Number of subjects: 18
Study: 4135024

Group type: EXPERIMENTAL
Intervention: Stimulated at the peak of alpha wave with clicks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulated midway on the up going portion of the wave with flashes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulated at the trough of the wave in the paired condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulated randomly
Number of subjects: 0
Study: 799990

Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: 10 mg temazepam
Number of subjects: 434
Study: 31433781

Group type: EXPERIMENTAL
Intervention: Combination of vitamin C and omega-3 polyunsaturated fatty acids (n-3 PUFA) given the day before surgery and for the first 5 days post-operation.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo control group receiving no active treatment.
Number of subjects: 160
Study: 29210875

Group type: EXPERIMENTAL
Intervention: Benson muscle relaxation
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Nature sounds
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study: 26924732

Group type: EXPERIMENTAL
Intervention: ULMbET
Number of subjects: 1648

Group type: COMPARATOR
Intervention: TA-UGET
Number of subjects: 1648
Study: 25198068

Group type: EXPERIMENTAL
Intervention: Devon Active Villages intervention providing 12 weeks of physical activity opportunities for all age groups, with at least three different types of activities per village.
Number of subjects: 10412

Group type: EXPERIMENTAL
Intervention: Devon Active Villages intervention
Number of subjects: 10412

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10412
Study: 22282373

Group type: EXPERIMENTAL
Intervention: Ghrelin (3 μg/kg) administered intravenously twice daily for 1 week with cisplatin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (saline) administered twice daily for 1 week with cisplatin
Number of subjects: 42
Study: 21171525

Group type: EXPERIMENTAL
Intervention: Ringerfundin infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma-Lyte infusion
Number of subjects: 0
Study: 18156664

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: CHO beverage
Number of subjects: 9

Group type: COMPARATOR
Intervention: PLAC beverage
Number of subjects: 9
Study: 15834591

Group type: EXPERIMENTAL
Intervention: Functional Rating Index (FRI)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Oswestry questionnaire
Number of subjects: 131
Study: 12422433

Group type: EXPERIMENTAL
Intervention: Qualitative interviews regarding patient perceptions of information disclosure during recruitment and throughout the study.
Number of subjects: 7
Study: 9814085

Group type: EXPERIMENTAL
Intervention: Chronic dietary fibre supplementation (doubled from 17.5 g/day to 34.4 g/day)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cessation of fibre supplementation
Number of subjects: 5
Study: 8129764

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: sIL-2R level
Number of subjects: 148
Study: 2912326

Group type: EXPERIMENTAL
Intervention: Combination aerosol of 100 micrograms beclomethasone dipropionate and 200 micrograms salbutamol, administered four times a day for 4 weeks.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Doubling the standard dose of salbutamol (400 micrograms), administered four times a day for 4 weeks.
Number of subjects: 57
Study: 1056054

Group type: EXPERIMENTAL
Intervention: Experimental group (stress condition with distracting noises)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no stress)
Number of subjects: 120
Study: 31664968

Group type: EXPERIMENTAL
Intervention: Trauma-informed yoga
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trauma-informed drumming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 28251555

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (1-2 post-tetanic counts)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (train-of-four ratio 10%)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Standard insufflation pressure (12 mmHg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Low insufflation pressure (8 mmHg)
Number of subjects: 127
Study: 25344632

Group type: EXPERIMENTAL
Intervention: Infarct volume
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Infarct volume alone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Infarct volume adjusted for race, systolic blood pressure, and NIHSS
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Infarct volume cut point of 6.8 cm(3)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Infarct volume greater than 3 cm(3)
Number of subjects: 46
Study: 24733799

Group type: EXPERIMENTAL
Intervention: Doxepin oral rinse
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 23014494

Group type: EXPERIMENTAL
Intervention: Mothers supplemented with 2 doses of 200,000 iu retinol (n = 13)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mothers nonsupplemented (n = 19)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups of mothers
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Infants' VA intake from breast milk
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Infants' VA liver stores assessed by MRDR test
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Plasma retinol
Number of subjects: 34
Study: 19542901

Group type: EXPERIMENTAL
Intervention: Alglucosidase alpha 20 mg/kg biweekly
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Alglucosidase alpha 40 mg/kg biweekly
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Alglucosidase alpha treatment
Number of subjects: 18
Study: 17103488

Group type: EXPERIMENTAL
Intervention: Pancreatin (Creon)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15119162

Group type: EXPERIMENTAL
Intervention: Acupuncture at point Neiguan (PC 6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 0
Study: 11329522

Group type: EXPERIMENTAL
Intervention: Quality care for depression (QI interventions)
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1104
Study: 9413463

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1000 mg three times a day
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 8215283

Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Mebendazole and Albendazole
Number of subjects: 337
Study: 2824623

Group type: EXPERIMENTAL
Intervention: 5 X 10(4) units of human leukocyte interferon/kg of body weight for 12 doses over 14 days (total, approximately 3.6 X 10(7) units)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo in equivalent volumes
Number of subjects: 34
Study: 31991284

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30362226

Group type: EXPERIMENTAL
Intervention: Neck cooling device
Number of subjects: 65

Group type: COMPARATOR
Intervention: No neck cooling device (control)
Number of subjects: 65
Study: 28512158

Group type: EXPERIMENTAL
Intervention: Diet only
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Exercise plus diet
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Total body fat
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Subcutaneous abdominal fat
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Intra-abdominal fat change
Number of subjects: 243
Study: 26244299

Group type: EXPERIMENTAL
Intervention: OCT angiography
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fluorescein angiography (FA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Indocyanine green angiography (ICGA)
Number of subjects: 24
Study: 23939297

Group type: EXPERIMENTAL
Intervention: Healthiest tertile of modified Alternate Healthy Eating Index (mAHEI) score
Number of subjects: 6213

Group type: EXPERIMENTAL
Intervention: More than 3 servings of fruits per week
Number of subjects: 6213

Group type: EXPERIMENTAL
Intervention: Lowest tertile of total and animal protein intake
Number of subjects: 6213

Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake
Number of subjects: 6213

Group type: COMPARATOR
Intervention: Sodium intake
Number of subjects: 6213

Group type: COMPARATOR
Intervention: Normal protein intake
Number of subjects: 6213
Study: 20535539

Group type: EXPERIMENTAL
Intervention: Melatonin (maximum dose of 10 mg for 3 months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (for 3 months)
Number of subjects: 22
Study: 18322413

Group type: EXPERIMENTAL
Intervention: AI-G regimen (doxorubicin and ifosfamide)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EIA regimen (etoposide, ifosfamide and doxorubicin)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Decrease in standardized uptake value (SUV; responders)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Increase or stable SUV (non-responders)
Number of subjects: 27
Study: 17184489

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1.2 g/day)
Number of subjects: 5375

Group type: EXPERIMENTAL
Intervention: Paracetamol (4.0 g/day)
Number of subjects: 5375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5375
Study: 12750137

Group type: EXPERIMENTAL
Intervention: Postoperative drain for 24 hours (12 patients)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No drain (9 patients)
Number of subjects: 21
Study: 10756221

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory agents (specific agents not mentioned)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1041
Study: 9058221

Group type: EXPERIMENTAL
Intervention: 0.5 MAC desflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 MAC isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 MAC desflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 MAC isoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no anesthetic agent)
Number of subjects: 60
Study: 8334749

Group type: EXPERIMENTAL
Intervention: Gestagen (500 micrograms/day of Promegestone for 21 days out of a 28-day cycle)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Gestagen
Number of subjects: 35
Study: 3555163

Group type: EXPERIMENTAL
Intervention: Continuous bupivacaine epidural analgesia
Number of subjects: 30
Study: 27283375

Group type: EXPERIMENTAL
Intervention: Resistance exercise with blood flow restriction (BFR) at 20% of one repetition maximum (1RM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Traditional high‐intensity resistance exercise at 65% of 1RM
Number of subjects: 18
Study: 27257857

Group type: EXPERIMENTAL
Intervention: Internet-delivered pain management program (Pain Course)
Number of subjects: 463
Study: 25522380

Group type: EXPERIMENTAL
Intervention: Dose reduction intervention (removal of one antipsychotic medication each week, reducing dose by 0 to 50 chlorpromazine equivalents)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Observation group (no intervention)
Number of subjects: 163
Study: 23312053

Group type: EXPERIMENTAL
Intervention: OM-3 FFA (Epanova)
Number of subjects: 54

Group type: COMPARATOR
Intervention: OM-3 EE (Lovaza)
Number of subjects: 54
Study: 20589465

Group type: EXPERIMENTAL
Intervention: Wholesome, nutritionally balanced mid day meal (MDM) provided by an NGO
Number of subjects: 221

Group type: COMPARATOR
Intervention: Locally prepared MDM by village panchayats
Number of subjects: 221
Study: 18705806

Group type: EXPERIMENTAL
Intervention: Z250 composite
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Freedom composite
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fuji IX glass‐ionomer cement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vitremer resin‐modified glass‐ionomer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20% sucrose solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 12
Study: 16444905

Group type: EXPERIMENTAL
Intervention: Loracarbef 15 mg/kg/day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Loracarbef 30 mg/kg/day
Number of subjects: 58
Study: 11434164

Group type: EXPERIMENTAL
Intervention: Nephrotic syndrome acute phase
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nephrotic syndrome remission phase
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 9717017

Group type: EXPERIMENTAL
Intervention: Single plane two-dimensional echocardiograms
Number of subjects: 371

Group type: COMPARATOR
Intervention: Biplane Simpson's method
Number of subjects: 371
Study: 8281693

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE), 35 micrograms, intravenous administration
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 33
Study: 2688360

Group type: EXPERIMENTAL
Intervention: 3 g/day of TISACID (acid‐neutralizing capacity = 78 mmol)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 6 g/day of TISACID (acid‐neutralizing capacity = 156 mmol)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 12 g/day of TISACID (acid‐neutralizing capacity = 312 mmol)
Number of subjects: 332

Group type: COMPARATOR
Intervention: 1.0 g/day cimetidine (HISTODIL)
Number of subjects: 332
Study: 19473593

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg (PIO45)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 372777

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 30700178

Group type: EXPERIMENTAL
Intervention: Immediate removal of urinary catheter (0h)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Intermediate removal of urinary catheter (6h)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Delayed removal of urinary catheter (24h)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Early removal of urinary catheter (0h)
Number of subjects: 221
Study: 28913703

Group type: EXPERIMENTAL
Intervention: Personalized literacy instruction supported by A2i technology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 0
Study: 29110698

Group type: EXPERIMENTAL
Intervention: Immediate radiographer report of GP CXR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard radiographer GP CXR reporting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate reporting of GP CXRs
Number of subjects: 0
Study: 26049689

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine (gem)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Observation (obs)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine (gem) with high hENT1 expression
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine (gem) with low hENT1 expression
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine (gem) with no hENT1 expression
Number of subjects: 156

Group type: COMPARATOR
Intervention: Observation (obs) with high hENT1 expression
Number of subjects: 156

Group type: COMPARATOR
Intervention: Observation (obs) with low hENT1 expression
Number of subjects: 156

Group type: COMPARATOR
Intervention: Observation (obs) with no hENT1 expression
Number of subjects: 156
Study: 24120952

Group type: EXPERIMENTAL
Intervention: Immediate psychodynamic psychotherapy for 12 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Delayed psychodynamic psychotherapy after 3 months
Number of subjects: 15
Study: 22020354

Group type: EXPERIMENTAL
Intervention: Casopitant 80 mg/d
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Casopitant 30 mg/d
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Casopitant 120 mg/d
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Paroxetine 30 mg/d
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study: 19410509

Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg, 450mg, and 600mg daily
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Pregabalin 450mg and 600mg
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1493
Study: 17406926

Group type: EXPERIMENTAL
Intervention: Interesterified palm oil (IPO)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Native palm oil (NPO)
Number of subjects: 38

Group type: COMPARATOR
Intervention: High-oleic sunflower oil (HOS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All test meals
Number of subjects: 38
Study: 15545560

Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior 90 degrees partial fundoplication
Number of subjects: 112

Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 112

Group type: COMPARATOR
Intervention: Both procedures
Number of subjects: 112
Study: 11169968

Group type: EXPERIMENTAL
Intervention: HPV DNA prevalence in women under 25 years
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: HPV DNA prevalence in women aged 35-44 years
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: HPV DNA prevalence in women aged 65 years and older
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: Cancer-associated HPV types
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: Non-cancer-associated HPV types
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: Intensity of polymerase chain reaction signal in younger women
Number of subjects: 1340
Study: 9892887

Group type: EXPERIMENTAL
Intervention: Debriefing intervention by midwives (n = 56)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No debriefing intervention (Control group, n = 58)
Number of subjects: 120
Study: 8052479

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, doxorubicin and mitomycin C (arm A)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 5-fluorouracil alone (arm B)
Number of subjects: 81
Study: 2839000

Group type: EXPERIMENTAL
Intervention: Air-polishing instrument (Prophy Unit, 2000 Satelec)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rubber cup with standardized solution of pumice
Number of subjects: 18
Study: 31797680

Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) using 90yttrium resin microspheres
Number of subjects: 85

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 85
Study: 30913244

Group type: EXPERIMENTAL
Intervention: Optimal allocation procedures for the Welch‐Satterthwaite tests of standardized and unstandardized contrasts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed allocation strategies combining nonlinear optimization search and iterative screening process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer algorithms developed for power and sample size calculations
Number of subjects: 0
Study: 28639369

Group type: EXPERIMENTAL
Intervention: Patients with diabetes (n = 922)
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Patients without diabetes (n = 1111)
Number of subjects: 2033
Study: 26550813

Group type: COMPARATOR
Intervention: oral treatment only with gabapentin + celecoxib + amitriptyline
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: radiofrequency (RF) pulses using a portable ultrasound device
Number of subjects: 128
Study: 23249532

Group type: EXPERIMENTAL
Intervention: High tone electrical muscle stimulation (HTEMS) performed intradialytically for 1 hour.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no HTEMS).
Number of subjects: 34
Study: 21481147

Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterisation (CIC)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Transurethral indwelling catheterisation (TIC)
Number of subjects: 87
Study: 19500141

Group type: EXPERIMENTAL
Intervention: Intravenous hydration with isotonic saline + N-acetylcysteine (600 mg p.o. twice daily the preceding day and the day of angiography), n = 73
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Intravenous hydration with isotonic saline + N-acetylcysteine + theophylline (600 mg N-acetylcysteine p.o. and 200 mg theophylline p.o. twice daily for the preceding day and the day of angiography), n = 72
Number of subjects: 217

Group type: COMPARATOR
Intervention: Intravenous hydration with isotonic saline, n = 72
Number of subjects: 217
Study: 16838577

Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation (EECP) treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study: 14626848

Group type: EXPERIMENTAL
Intervention: Bayesian method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple logistic regression method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple stepwise regression method
Number of subjects: 0
Study: 11491133

Group type: EXPERIMENTAL
Intervention: Chloral hydrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study: 9544646

Group type: EXPERIMENTAL
Intervention: Additional procedures after initial vitrectomy (VIT) or tap-biopsy (TAP)
Number of subjects: 420
Study: 7868846

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 1447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1447
Study: 2543143

Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acid eicosapentaenoate (EPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet rich in marine lipids
Number of subjects: 0